Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Gastrointestinal 2Thoracic 1Plasma cell 1Gynecologic 1Endocrine 1CNS 1Breast 1

Conditions

Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Dexamethasone 374Lenalidomide 206Bortezomib 201Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Electrocardiography × Plasma cell × Clear all
NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡